Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report:

Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary... Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with poor prognosis. The skipping mutation in exon 14 of MET, an oncogenic driver of NSCLC, occurs more frequently in PSC than other subtypes. Treatment options for patients with PSC include targeted therapies and immunotherapies, while the best treatment regimen has not been established due to limited number of patients. In this report, we presented a case with metastatic PSC harboring MET 14 exon skipping mutation. The patient received crizotinib but soon acquired drug resistance. Then, the patient turned to immunotherapy in combination with chemotherapy and has achieved a progression-free survival for 15 months as of the data cutoff date. The comprehensive genomic sequencing after crizotinib resistance revealed additional genetic alterations such as CD274 (also known as programmed cell death ligand 1) amplification which might be associated with treatment response of the patient. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Medicine Insights: Oncology SAGE

Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report:

Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report:

Clinical Medicine Insights: Oncology , Volume 16: 1 – Jan 27, 2022

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with poor prognosis. The skipping mutation in exon 14 of MET, an oncogenic driver of NSCLC, occurs more frequently in PSC than other subtypes. Treatment options for patients with PSC include targeted therapies and immunotherapies, while the best treatment regimen has not been established due to limited number of patients. In this report, we presented a case with metastatic PSC harboring MET 14 exon skipping mutation. The patient received crizotinib but soon acquired drug resistance. Then, the patient turned to immunotherapy in combination with chemotherapy and has achieved a progression-free survival for 15 months as of the data cutoff date. The comprehensive genomic sequencing after crizotinib resistance revealed additional genetic alterations such as CD274 (also known as programmed cell death ligand 1) amplification which might be associated with treatment response of the patient.

Loading next page...
 
/lp/sage/treatment-response-to-immunotherapy-after-crizotinib-resistance-in-a-RJHCYTx0YL

References (18)

  • S. Clavé, L. Pijuan, D. Casadevall, Á. Taus, J. Gimeno, Silvia Hernández-Llodrà, M. Rodríguez-Rivera, M. Lorenzo, S. Menéndez, J. Albanell, B. Espinet, E. Arriola, M. Salido (2018)

    CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients

    Histopathology, 72

  • J. George, M. Saito, K. Tsuta, Reika Iwakawa, K. Shiraishi, A. Scheel, S. Uchida, Shun-ichi Watanabe, R. Nishikawa, M. Noguchi, M. Peifer, S. Jang, I. Petersen, R. Büttner, C. Harris, J. Yokota, Roman Thomas, T. Kohno (2016)

    Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

    Clinical Cancer Research, 23

  • A. Addeo, A. Passaro, U. Malapelle, Giuseppe Banna, V. Subbiah, A. Friedlaender (2021)

    Immunotherapy in non-small cell lung cancer harbouring driver mutations.

    Cancer treatment reviews, 96

  • Eric Be, Eric Be, E. Collisson, Joshua Campbell, Angela Brooks, A. Berger, William Lee, J. Chmielecki, D. Beer, L. Cope, C. Creighton, Ludmila Danilova, L. Ding, G. Getz, P. Hammerman, D. Hayes, Bryan Hernandez, J. Herman, J. Heymach, I. Jurisica, R. Kucherlapati, D. Kwiatkowski, M. Ladanyi, Gordon Robertson, N. Schultz, R. Shen, Rileen Sinha, C. Sougnez, M. Tsao, W. Travis, J. Weinstein, D. Wigle, M. Wilkerson, Andy Chu, A. Cherniack, Angela Hadjipanayis, Mara Rosenberg, D. Weisenberger, P. Laird, Amie Radenbaugh, Singer Ma, Joshua Stuart, Lauren Byers, S. Baylin, R. Govindan, M. Meyerson, Mara Li, S. Gabriel, K. Cibulskis, Jaegil Kim, C. Stewart, Lee Lichtenstein, E. Lander, M. Lawrence, Cyriac M, C. Kandoth, R. Fulton, L. Fulton, M. McLellan, R. Wilson, K. Ye, C. Fronick, Christopher Maher, Christopher Miller, M. Wendl, Christopher Cabanski, E. Mardis, C. Wheeler, David Wheeler, Miruna Dhalla, M. Balasundaram, Y. Butterfield, R. Carlsen, E. Chuah, Noreen Dhalla, R. Guin, Carrie Hirst, Darlene Lee, H. Li, Michael Mayo, Richard Moore, A. Mungall, J. Schein, Payal Sipahimalani, Angela Tam, R. Varhol, A. Robertson, N. Wye, N. Thiessen, R. Holt, Steven Jones, M. Marra, Joshua Hodi, M. Imieliński, R. Onofrio, Eran Hodis, Travis Zack, E. Helman, Chandra Pedamallu, J. Mesirov, G. Saksena, S. Schumacher, S. Carter, L. Garraway, R. Beroukhim, Angela Re, Semin Lee, Harshad Mahadeshwar, A. Pantazi, A. Protopopov, X. Ren, S. Seth, Xingzhi Song, Jiabin Tang, Lixing Yang, Jianhua Zhang, Peng-Chieh Chen, Michael Parfenov, Andrew Xu, Netty Santoso, L. Chin, Peter Park, Katherine T, K. Hoadley, J. Auman, S. Meng, Yan Shi, Elizabeth Buda, S. Waring, Umadevi Veluvolu, Donghui Tan, P. Mieczkowski, Corbin Jones, J. Simons, Matthew Soloway, T. Bodenheimer, S. Jefferys, J. Roach, A. Hoyle, Junyuan Wu, S. Balu, Darshan Singh, J. Prins, J. Marron, J. Parker, C. Perou, Jinze Liu, Leslie Bootwalla, D. Maglinte, Philip Lai, M. Bootwalla, D. Berg, Timothy Jr, Mara Mallard, Juok Cho, D. Dicara, David Heiman, Pei Lin, William Mallard, Douglas Voet, Hailei Zhang, L. Zou, M. Noble, N. Gehlenborg, H. Thorvaldsdóttir, Marc-Danie Nazaire, Jim Robinson, William Gross, B. Aksoy, G. Ciriello, B. Taylor, Gideon Dresdner, Jianjiong Gao, Benjamin Gross, V. Seshan, B. Reva, Rileen Sinha, S. Sumer, Nils Weinhold, C. Sander, Sam Haussler, S. Ng, Jingchun Zhu, C. Benz, C. Yau, D. Haussler, P. Spellman, Matthew Perou, P. Kimes, Bradley Liu, B. Broom, Jing Wang, Yiling Lu, Patrick Ng, L. Diao, Wenbin Liu, C. Amos, R. Akbani, G. Mills, Erin Gardn, Erin Curley, J. Paulauskis, Kevin Lau, S. Morris, T. Shelton, D. Mallery, J. Gardner, R. Penny, Charles Tarvin, Charles Saller, Katherine Tarvin, W. Richards, Robert Bryant, R. Cerfolio, A. Bryant, Daniel Farver, D. Raymond, N. Pennell, C. Farver, Christine Raben, Christine Czerwinski, L. Huelsenbeck-Dill, M. Iacocca, N. Petrelli, B. Rabeno, Jennifer Brown, Thomas Bauer, Oleg Nemirovich-Dan, O. Dolzhanskiy, O. Potapova, D. Rotin, Olga Voronina, Elena Nemirovich-Danchenko, K. Fedosenko, Anthony Sica, A. Gal, M. Behera, S. Ramalingam, G. Sica, Douglas Weaver, D. Flieder, J. Boyd, J. Weaver, Bernard Thinh, B. Kohl, Dang Thinh, G. Sandusky, Hartmut Juhl, E. Duhig, Peter Brock, P. Illei, E. Gabrielson, James Shin, Beverly Lee, Kristen Rodgers, D. Trusty, M. Brock, Christina Sullivan, C. Williamson, E. Burks, K. Rieger-Christ, A. Holway, T. Sullivan, Dennis Kosari, M. Asiedu, F. Kosari, William Rusch, N. Rekhtman, M. Zakowski, V. Rusch, Paul Owusu-Sarpong, Paul Zippile, James Suh, H. Pass, C. Goparaju, Y. Owusu-Sarpong, John Albert, John Bartlett, S. Kodeeswaran, J. Parfitt, H. Sekhon, Monique Albert, John Myers, J. Eckman, J. Myers, Richard Gaudioso, R. Cheney, Carl Morrison, Carmelo Gaudioso, Jeffrey Liptay, J. Borgia, P. Bonomi, M. Pool, M. Liptay, Fedor Zaytseva, F. Moiseenko, I. Zaytseva, Hendrik Muley, H. Dienemann, M. Meister, P. Schnabel, T. Muley, M. Peifer, Carmen Egea, C. Gomez-Fernandez, Lynn Herbert, Sophie Egea, Mei Kimryn, Mei Huang, L. Thorne, L. Boice, Ashley Salazar, W. Funkhouser, W. Rathmell, Rajiv Siegfried, R. Dhir, S. Yousem, S. Dacic, F. Schneider, J. Siegfried, R. Hajek, Mark Meyers, M. Watson, Sandra McDonald, B. Meyers, Belinda Bowman, B. Clarke, I. Yang, K. Fong, L. Hunter, M. Windsor, R. Bowman, Solange Letovanec, Solange Peters, I. Letovanec, K. Khan, Mark Pot, M. Jensen, E. Snyder, Deepak Srinivasan, A. Kahn, J. Baboud, D. Pot, Kenna Tarnuz, Kenna Shaw, Margi Sheth, Tanja Davidsen, John Demchok, Liming Yang, Zhining Wang, R. Tarnuzzer, Jean Zenklusen, Bradley Sofia, B. Ozenberger, H. Sofia, William Illei, E. Duhig (2014)

    Comprehensive molecular profiling of lung adenocarcinoma

    Nature, 511

  • Caibao Jin, B. Yang (2020)

    Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report

    Case Reports in Oncology, 13

  • Caiwen Huang, Q. Zou, Hui Liu, B. Qiu, Qi-wen Li, Yong-bin Lin, Ying-ying Liang (2020)

    Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations

    Current Treatment Options in Oncology, 21

  • J. Sabari, G. Leonardi, C. Shu, R. Umeton, J. Montecalvo, A. Ni, R. Chen, Jordan Dienstag, C. Mrad, I. Bergagnini, W. Lai, M. Offin, K. Arbour, A. Plodkowski, D. Halpenny, P. Paik, B. Li, Gregory Riely, M. Kris, C. Rudin, L. Sholl, M. Nishino, M. Hellmann, N. Rekhtman, M. Awad, A. Drilon (2018)

    PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

    Annals of Oncology, 29

  • Carrie Lee, Dimitry Usenko, G. Frampton, Caitlin McMahon, Siraj Ali, J. Weiss (2015)

    MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10 12

  • A. Cortot, Z. Kherrouche, C. Descarpentries, M. Wislez, S. Baldacci, A. Furlan, D. Tulasne (2017)

    Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

    Journal Of The National Cancer Institute, 109

  • M. Mayenga, J. Assié, I. Monnet, M. Massiani, L. Tabèze, S. Friard, S. Fraboulet, A. Metivier, C. Chouaïd, L. Zemoura, E. Longchampt, C. Callens, S. Melaabi, L. Couderc, H. Doubre (2020)

    Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.

    Lung cancer, 150

  • M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma Rangwala, J. Brahmer (2016)

    Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

    The New England journal of medicine, 375 19

  • Xuewen Liu, Yuxia Jia, M. Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, M. Mansukhani, S. Koul, B. Halmos, A. Borczuk (2016)

    Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 8

  • A. Sadiq, R. Salgia (2013)

    MET as a possible target for non-small-cell lung cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 8

  • A. Goodman, D. Piccioni, S. Kato, A. Boichard, Huan-You Wang, G. Frampton, S. Lippman, Caitlin Connelly, D. Fabrizio, V. Miller, J. Sicklick, R. Kurzrock (2018)

    Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

    JAMA Oncology, 4

  • G. Recondo, Magda Bahcall, Liam Spurr, Jianwei Che, B. Ricciuti, G. Leonardi, Y. Lo, Yvonne Li, G. Lamberti, Tom Nguyen, M. Milan, D. Venkatraman, R. Umeton, C. Paweletz, Adem Albayrak, A. Cherniack, K. Price, Stephen Fairclough, M. Nishino, L. Sholl, G. Oxnard, P. Jänne, M. Awad (2020)

    Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

    Clinical Cancer Research, 26

  • Keisuke Baba, Hisashi Tanaka, H. Sakamoto, Toshihiro Shiratori, Junichiro Tsuchiya, Yoshiko Ishioka, M. Itoga, K. Taima, S. Tasaka (2019)

    Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report

    Thoracic Cancer, 10

  • H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)

    Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

    The New England journal of medicine, 373 17

  • S. Yendamuri, Laura Caty, M. Pine, Soumya Adem, Paul Bogner, Austin Miller, T. Demmy, A. Groman, M. Reid (2012)

    Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis.

    Surgery, 152 3

Publisher
SAGE
Copyright
Copyright © 2022 by SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
eISSN
1179-5549
DOI
10.1177/11795549211067185
Publisher site
See Article on Publisher Site

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with poor prognosis. The skipping mutation in exon 14 of MET, an oncogenic driver of NSCLC, occurs more frequently in PSC than other subtypes. Treatment options for patients with PSC include targeted therapies and immunotherapies, while the best treatment regimen has not been established due to limited number of patients. In this report, we presented a case with metastatic PSC harboring MET 14 exon skipping mutation. The patient received crizotinib but soon acquired drug resistance. Then, the patient turned to immunotherapy in combination with chemotherapy and has achieved a progression-free survival for 15 months as of the data cutoff date. The comprehensive genomic sequencing after crizotinib resistance revealed additional genetic alterations such as CD274 (also known as programmed cell death ligand 1) amplification which might be associated with treatment response of the patient.

Journal

Clinical Medicine Insights: OncologySAGE

Published: Jan 27, 2022

Keywords: Non-small cell lung cancer; pulmonary sarcomatoid carcinoma; MET; exon skipping; crizotinib; nivolumab

There are no references for this article.